Microsoft word - document
US FDA approves Requip® XL™, the first and only oral once-daily non-ergot dopamine
agonist for Parkinson’s disease
Extended-release formulation improved symptoms in patients not optimally controlled
with levodopa and reduced patients’ “off” time by nearly two hours per day
GlaxoSmithKline today announced the approval of Requip®
tablets) in the U.S. for the treatment of the signs and symptoms of idiopathic Parkinson’s disease.
Itis the first and only oral once-daily non-ergot dopamine agonist indicated for Parkinson’s
disease. The product should be available in U.S. pharmacies in mid-July 2008.
Patients with Parkinson’s disease may experience what is commonly known as “off” time when their medication wears off and their symptoms return. Symptoms such as slowness of movement, tremor, and rigidity can be problematic for these patients, causing simple activities and movement to become difficult. Results from a pivotal efficacy and safety trial showed that adding extended-release ropinirole to patients’ existing levodopa (l-dopa) therapy reduced the amount of “off” time experienced by patients with Parkinson’s disease by 2.1 hours per day on average, compared to baseline. Specifically, comparing the experience of the group treated with extended-release ropinirole versus the placebo group, the adjusted mean difference in the reduction of “off” time was -1.7 hours, which was statistically significant.
“Many patients require multiple doses of one or more medications to control their Parkinson’s symptoms, which makes taking their medicines correctly and at the right times challenging. In addition, patients with Parkinson’s disease may have trouble completing routine activities of daily living and self-care,” said clinical investigator Rajesh Pahwa, M.D., professor of Neurology and director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center in Kansas City. “Requip XL
provides continuous delivery of ropinirole over 24 hours to provide smoother blood levels without the peaks and troughs that multiple daily doses typically deliver. It is an important once-daily treatment option for patients with Parkinson’s disease.”
is an extended-release, once-daily tablet formulation that uses SkyePharma PLC’s (LSE: SKP) patented GEOMATRIX™ technology. This innovative tri-layer formulation allows for continuous delivery of ropinirole over 24 hours to provide smooth blood levels. Extended-release ropinirole offers physicians and patients a simple titration regimen; it also offers a convenient, once-daily dosing schedule compared to other oral dopamine agonists, which are dosed multiple times a day.
FDA approval was based primarily on results from the EASE-PD (Efficacy And Safety Evaluation
in Parkinson Disease) Adjunct Study, a multi-center, double-blind, placebo-controlled study
conducted in patients with idiopathic Parkinson’s disease not adequately controlled with l-dopa.
A total of 393 patients in the study were randomized to receive either extended-release
ropinirole(n=202) or placebo (n=191) once daily for 24 weeks in addition to l-dopa. The study’s
primary endpoint was the mean change from baseline at week 24 in awake time spent “off”, which
was measured via patient diaries. Results from the study showed that extended-release
ropinirole significantly reduced “off” time by an average of 2.1 hours per day from baseline,
compared to a reduction of 0.4 hours per day for placebo.
Once-daily use of extended-release ropinirole was generally well tolerated in the study. The withdrawal rate due to adverse reactions was low and similar between groups (6 percent extended-release ropinirolevs. 5 percent placebo). The most common adverse reactions reported in patients taking extended-release ropinirole compared to placebo were dyskinesia (13 percent vs. 3 percent), nausea (11 percent vs. 4 percent), dizziness (8 percent vs. 3 percent),
hallucination (7 percent vs. 3 percent), somnolence (7 percent vs. 4 percent), abdominal pain/discomfort (6 percent vs. 3 percent) and orthostatic hypotension (5 percent vs. 1 percent).
A progressively disabling disease
Parkinson’s disease is a chronic, progressive, and often disabling neurological condition that
eventually impairs the body’s ability to move and balance. Researchers have determined that
Parkinson’s disease involves the degeneration of the cells in one of the brain areas responsible
for motor control. Patients with Parkinson’s disease experience a reduction in dopamine, a key
chemical in the brain that communicates messages about movement, resulting in the symptoms
of Parkinson’s disease. These symptoms include tremor (involuntary shaking), rigidity (stiffness),
akinesia (lack of movement or loss of spontaneous movement), bradykinesia (slower-than-normal
voluntary movements), and problems with walking, balance and posture.
More than one million people in the United States have Parkinson’s disease. The average age of onset of Parkinson’s disease is about 60 years, but the disease can develop at an earlier age.
About Requip XL Requip XL
Tablets are indicated in the U.S. for the treatment of the signs and symptoms of
idiopathic Parkinson’s disease and are administered once daily. Prescription Requip XL
is not for
everyone. Requip XL
may cause patients to fall asleep or feel very sleepy during normal
activities such as driving; or to faint or feel dizzy, nauseated, or sweaty when they stand up.
Patients should tell their doctor if they experience these effects or the following problems, or if
they drink alcohol or are taking other medicines that make them drowsy. Side effects may
include nausea, dizziness, drowsiness or sleepiness, headache, and sudden uncontrolled
movements (dyskinesia). Increase or decrease in blood pressure and heart rate may occur.
Hallucinations may occur at anytime during treatment. Patients should also tell their doctor if they
experience new or increased gambling, sexual, or other intense urges while taking Requip XL.
may increase the side effects of l-dopa. Most patients were not bothered enough to
stop taking Requip XL.
About SkyePharma PLC
Using its proprietary drug delivery technologies, SkyePharma develops new formulations of
existing products to provide a clinical advantage and life-cycle extension. The company has 12
approved products in the areas of oral, inhalation, and topical delivery. The Group’s products are
marketed throughout the world by leading pharmaceutical companies. For more information, visit
About GlaxoSmithKline Requip XL
was developed and is marketed by GlaxoSmithKline, one of the world’s leading
research-based pharmaceutical and healthcare companies. More information on
GlaxoSmithKline is available at the company’s Web site at www.gsk.com.
Cautionary statement regarding forward-looking statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995,
GSK cautions investors that any forward-looking statements or projections made by GSK,
including those made in this announcement, are subject to risks and uncertainties that may cause
actual results to differ materially from those projected. Factors that may affect GSK’s operations
are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on
Form 20-F for 2007.
For Full Prescribing Information for Requip XL
in the U.S., please call +1 919 483 2839 or visit www.gsk.com.
Editor’s Note: Requip XL
is currently approved in Austria, Belgium, Czech Republic, Denmark,
Estonia, Finland, France, Germany, Hungary, Ireland, Italy, Latvia, Lithuania, The Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, and United Kingdom.
Requip ® XL™
will also be known as Requip ® LP
, Requip-Modutab ® ,
and Requip ® Depot
Requip ® XL™, Requip ® LP
, Requip-Modutab ® ,
and Requip ® Depot
are trademarks of the
GlaxoSmithKline group of companies.
GEOMATRIX™ is a trademark of SkyePharma Plc.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 1998, p. 1778–1782Copyright © 1998, American Society for Microbiology. All Rights Reserved. NorM, a Putative Multidrug Efflux Protein, of Vibrio parahaemolyticus and Its Homolog in Escherichia coli YUJI MORITA,1 KAZUYO KODAMA,1 SUMIKO SHIOTA,1 TOMOYUKI MINE,1 ATSUKO KATAOKA,1TOHRU MIZUSHIMA,1 AND TOMOFUSA TSUCHIYA1,2,* Department of Microbiolo
Conducting a [email protected] Organizational Review: Getting Started Why do a [email protected] Organizational Review? A [email protected] Organizational Review of existing policies and practices related to the protection of your employees’ psychological health is the first step toward determining the extent to which your workplace is psychologically safe. A psychologically healthy and safe workplace is one that promotes empl